Mortality Rates High for People Successfully Treated for Hep C
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 9, 2023 -- Mortality rates are high for people successfully treated for hepatitis C virus (HCV) in the era of interferon-free direct-acting antivirals, according to a study published online Aug. 2 in The BMJ.
Victoria Hamill, Ph.D., from Glasgow Caledonian University in the United Kingdom, and colleagues conducted a population-based cohort study involving 21,790 people from British Columbia (Canada), Scotland, and England who were successfully treated for HCV in the era of interferon-free antivirals (2014 to 2019) to quantify mortality rates. Participants were divided into three groups according to liver disease severity: those without cirrhosis; those with compensated cirrhosis; and those with end-stage liver disease.
During follow-up, 7 percent of participants died. The researchers found that the leading causes of death were drug-related mortality, liver failure, and liver cancer (24, 18, and 16 percent, respectively). Across all disease severity groups and settings, all-cause mortality was considerably higher than the rate for the general population (e.g., standardized mortality ratios, 2.96 and 13.61 for people without cirrhosis in British Columbia and for patients with end-stage liver disease in British Columbia, respectively). Older age, recent substance misuse, alcohol misuse, and comorbidities were associated with higher mortality rates in regression analyses.
"These findings highlight the importance of establishing robust follow-up pathways after successful HCV treatment as we move towards HCV elimination," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Higher Hepatitis C Virus Cure Rates Seen With Facilitated Telemedicine
FRIDAY, April 12, 2024 -- Significantly higher hepatitis C virus cure rates are seen for patients receiving opioid treatment program-integrated facilitated telemedicine versus...
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial...
Guideline Updated for Managing Hepatitis C in Chronic Kidney Disease
TUESDAY, Dec. 12, 2023 -- The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on prevention, diagnosis, evaluation, and treatment of hepatitis C in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.